Table 4

Cause-specific hazard ratios of stroke in patients without prior SAE

Nested case–control study
HR (95% CI)
logCRP1.14 (0.90 to 1.45)
% of full physical function, per 10 points0.88 (0.79 to 0.97)
No CV disease (Reference)
 CV disease with therapy1.13 (0.65 to 1.98)
 CV disease and no therapy2.27 (1.15 to 4.49)
csDMARD (Reference)
 TNFi0.73 (0.43 to 1.24)
 Other bDMARDs0.65 (0.30 to 1.41)
No of previous bDMARDs1.18 (0.86 to 1.62)
Glucocorticoids, current by 5 mg/day0.74 (0.52 to 1.04)
Non-selective NSAIDs1.34 (0.78 to 2.32)
Cox-2 inhibitors1.38 (0.70 to 2.71)
  • Patients are censored at the end of the observation (index date) or at the occurrence of other SAEs, whatever comes first.

  • bDMARD, biological disease-modifying anti-rheumatic drug; COX-2 inhibitors, inhibitors of cyclooxygenase-2.; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CV, cardiovascular; NSAID, non-steroidal antirheumatic drug; SAE, serious adverse events; TNFi, inhibitors of tumour necrosis factor alpha.